In vitro susceptibility of dermatophytes isolated from patients with end-stage renal disease: A case-control study

Mycoses

Volumn 57, Issue 3, 2014, Pages 129-134

  Irimie, Marius ^a   Tǎtaru, Alexandru ^b   Oantǎ, Alexandru ^a   Moga, Marius ^a  

^a TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Antifungals; Chronic kidney disease; Dermatophyte; in vitro susceptibility

Indexed keywords

AGAR; CREATININE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; SABOURAUD AGAR; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DERMATOPHYTE; DERMATOPHYTOSIS; END STAGE RENAL DISEASE; EPIDERMOPHYTON FLOCCOSUM; FEMALE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; HEMODIALYSIS; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MICROSPORUM CANIS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

ARTHRODERMATACEAE; TRICHOPHYTON RUBRUM;

ANTIFUNGALS; CHRONIC KIDNEY DISEASE; DERMATOPHYTE; IN VITRO SUSCEPTIBILITY;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CASE-CONTROL STUDIES; CREATININE; DERMATOMYCOSES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS; TRICHOPHYTON; YOUNG ADULT;

EID: 84893782349     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12114     Document Type: Article

References (29)

1. Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol 2010; 28: 197.
2. Kuvandik G, Çetin M, Genctoy G et al. The prevalence, epidemiology and risk factors for onychomycosis in hemodialysis patients. BMC Infect Dis 2007; 7: 102.
3. Dyachenko P, Monselise A, Shustak A, Ziv M, Rozenman D. Nail disorders in patients with chronic renal failure and undergoing haemodialysis treatment: a case-control study. J Eur Acad Dermatol Venereol 2007; 21: 340-4.
4. Abdelaziz AM, Mahmoud KM, Elsawy EM, Bakr MA. Nail changes in kidney transplant recipients. Nephrol Dial Transplant 2010; 25: 274-7.
5. Bencini PL, Montagnino G, Citterio A, Graziani G, Crosti C, Ponticelli C. Cutaneous abnormalities in uremic patients. Nephron 1985; 40: 316-21.
6. Pico MR, Lugo-Somolinos A, Sanchez JL, Burgos-Calderon R. Cutaneous alterations in patients with chronic renal failure. Int J Dermatol 1992; 31: 860-3.
7. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Susceptibility Testing of Conidium-Forming Filamentous Fungi: Proposed Standard. M38-P. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.
8. Jessup CJ, Warner J, Isham N et al. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-4.
9. Ghannoum MA, Chatuverdi V, Espinel-Ingroff A et al. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol 2004; 42: 2977-9.
10. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149: 296-305.
11. McKerrow KJ, Hawthorn RJ, Thompson W. An investigation of circulating and in situ lymphocyte subsets in Langerhans' cells in the skin and cervix of patients with chronic renal failure. Br J Dermatol 1989; 120: 745-55.
12. Gilchrest BA, Rowe JW, Mihm MC. Clinical and histological skin changes in chronic renal failure: evidence for a dialysis-resistant, transplant-responsive microangiopathy. Lancet 1980; 2: 1271-5.
13. Lundin AP, Fani K, Berlyne GM, Friedman EA. Dermal angiopathy in hemodialysis patients: the effect of the time. Kidney Int 1995; 47: 1775-80.
14. Tercedor J, Lopez Hemandez B, Manuel rodenas J. Nail diseases in haemodialysis patients: case-control study. Br J Dermatol 2001; 144: 445-6.
15. Altmeyer P, Kachel HG, Junger M, Koch KM, Holzmann H. Skin changes in long term dialysis patients. Clinical study. Hautarzt 1982; 33: 137-42.
16. Fernández-Torres B, Cabañes FJ, Carrillo-Munõz AJ et al. Collaborative evaluation of optimal antifungal susceptibility testing condition for dermatophytes. J Clin Microbiol 2002; 40: 3999-4003.
17. Evans EGV, Sigurgeirsson B. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. Br Med J 1999; 318: 1031-5.
18. Magagnin CM, Stopiglia CD, Vieira FJ et al. Antifungal susceptibility of dermatophytes isolated from patients with chronic renal failure. An Bras Dermatol 2011; 86: 694-701.
19. Favre B, Hofbauer B, Hildering K, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003; 41: 4817-9.
20. 14C] fluconazole in humans. Drug Metab Dispos 1991; 19: 764-7.
21. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500.
22. Gandhi BV, Bahadur MM, Dodeja H, Aggrwal V, Thamba A, Mali M. Systemic fungal infections in renal diseases. J Postgrad Med 2005; 51(Suppl. 1): 30-6.
23. Berl T, Wilner KD, Gardner M, et al. . Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995; 6: 242-7.
24. Bennett WM, Aronoff GR, Golper TA et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults, 4th edn. Philadelphia: American College of Physicians; 1999.
25. Johnson RJ, Blair AD, Ahmad S. Ketoconazole kinetics in chronic peritoneal dialysis. Clin Pharmacol Ther 1985; 37: 325-9.
26. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61(Suppl. 1): 27-37.
27. Boelaert J, Schurgers M, Matthys E et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988; 32: 1595-7.
28. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
29. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43(Suppl. 1): 28-39.